Article Per Year (5 Year)
p-Index From 2020 - 2025
0
P-Index
This Author published in this journals
All Journal Indonesian Journal of Cancer
Lenny Sari, Lenny
Unknown Affiliation
Health Professions

Published : 5 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 5 Documents
Search

 1 
Liquid-based Cytology (LBC) Method for Gynecologic Cytology Sari, Lenny
Indonesian Journal of Cancer Vol 4, No 5 (2010): Workshops 2010
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Liquid-based Cytology (LBC) Method for Gynecologic Cytology Full text : http://www.scribd.com/doc/43597706/Liquid-based-Cytology-LBC-Method-for-Gynecologic-Cytology
Pemeriksaan Pap’s Smear dengan Metode Thinprep Sari, Lenny
Indonesian Journal of Cancer Vol 2, No 2 (2008): Apr - Jun 2008
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1230.947 KB)

Abstract

Pemeriksaan melalui metode ThinPrep telah diakui oleh FDA (The US Food and Drug Administration) untuk menggantikan pemeriksaan Paps smear konvensional sejak tahun 1996 untuk mendeteksi sel atipik, lesi prakanker dan kanker serviks sesuai dengan Sistem pelaporan Paps smear melalui Bethesda Sistem. Penelitian menyebutkan metode ThinPrep Pap test secara signifikan lebih efektif dibanding metode Pap smear konvensional dalam mendeteksi lesi prakanker Low Grade Squamous Intraepithelial Lesion (LSIL) ataupun kelainan lebih lanjut. Hasil negatif palsu dari Pap smear konvensional terjadi karena kesalahan pada pengambilan bahan/sample dan pada pembuatan sediaan. Pada Pap smear konvensional hanya sebagian sel yang diapuskan pada gelas objek yang menghasilkan apusan yang tidak monolayer serta sebagian dari sel-sel kemudian ikut terbuang dengan sikat endoserviks. ThinPrep Pap test akan menghasilkan kualitas spesimen yang lebih baik secara signifikan dibandingkan dengan Pap smear konvensional dan disamping itu proses skrining menjadi lebih cepat serta dapat dilakukan pemeriksaan lebih lanjut terhadap HPV ataupun pembuatan cell block.Kata kunci : Konvensional Paps smear, Thin Prep Pap tes
Mutasi EGFR pada Non-Small Cell Lung Cancer di Rumah Sakit Kanker “Dharmais” SARI, LENNY; PURWANTO, PURWANTO
Indonesian Journal of Cancer Vol 10, No 4 (2016): October - December 2016
Publisher : Indonesian Journal of Cancer

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (528.765 KB)

Abstract

ABSTRACTThis descriptive study illustrated the proportion of EGFR mutation in non-small cell lung cancer (NSCLC) at “Dharmais” National Cancer Hospital. Examination of EGFR mutation started in 2015, 196 data was collected and 68 data being analyses. Fixed Formalin Paraffin Embedded (FFPE) processed by cobas® 4800 real time polymerase chain reaction. The results shown 34% patients NSCLC with EGFR mutation and all of them was single mutation. EGFR mutation happens in Exon 21 L858R 10 cases (44 %), Exon 19del 12 cases (52 %) and the type of Exon 20 S768I 1 case (4 %). This study found a high proportion of EGFR mutation.ABSTRAKStudi deskriptif ini menggambarkan proporsi mutasi Epidermal Growth Factor Receptor (EGFR) pada pasien dengan kanker paru di Rumah Sakit Kanker “Dharmais”. Telah terkumpul 196 data, tetapi terdapat 68 data yang telah selesai dilakukan pemeriksaan mutasi EGFR. Mutasi EGFR diperiksa menggunakan Formalin-Fixed Paraffin-Embedded (FFPE) dengan teknologi cobas® 4800 real-time polymerase chain reaction. Ditemukan 34% pasien dengan mutasi EGFR. Pada kelompok tersebut hanya ditemukan single mutation. Mutasi EGFR terjadi pada Exon 21 L858R sebanyak 10 kasus (44%), Exon 19del 12 kasus (52%), dan tipe Exon 20 S768I sebanyak 1 kasus (4%). Studi ini masih berlangsung dan diharapkan dapat memberikan gambaran yang lebih komprehensif tentang mutasi EGFR pada kanker paru.
Mutasi EGFR pada Non-Small Cell Lung Cancer di Rumah Sakit Kanker “Dharmais” SARI, LENNY; PURWANTO, PURWANTO
Indonesian Journal of Cancer Vol 10, No 4 (2016): October - December 2016
Publisher : Indonesian Journal of Cancer

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (528.765 KB)

Abstract

ABSTRACTThis descriptive study illustrated the proportion of EGFR mutation in non-small cell lung cancer (NSCLC) at “Dharmais” National Cancer Hospital. Examination of EGFR mutation started in 2015, 196 data was collected and 68 data being analyses. Fixed Formalin Paraffin Embedded (FFPE) processed by cobas® 4800 real time polymerase chain reaction. The results shown 34% patients NSCLC with EGFR mutation and all of them was single mutation. EGFR mutation happens in Exon 21 L858R 10 cases (44 %), Exon 19del 12 cases (52 %) and the type of Exon 20 S768I 1 case (4 %). This study found a high proportion of EGFR mutation.ABSTRAKStudi deskriptif ini menggambarkan proporsi mutasi Epidermal Growth Factor Receptor (EGFR) pada pasien dengan kanker paru di Rumah Sakit Kanker “Dharmais”. Telah terkumpul 196 data, tetapi terdapat 68 data yang telah selesai dilakukan pemeriksaan mutasi EGFR. Mutasi EGFR diperiksa menggunakan Formalin-Fixed Paraffin-Embedded (FFPE)dengan teknologi cobas® 4800 real-time polymerase chain reaction. Ditemukan 34% pasien dengan mutasi EGFR. Pada kelompok tersebut hanya ditemukan single mutation. Mutasi EGFR terjadi pada Exon 21 L858R sebanyak 10 kasus (44%), Exon 19del 12 kasus (52%), dan tipe Exon 20 S768I sebanyak 1 kasus (4%). Studi ini masih berlangsung dan diharapkan dapat memberikan gambaran yang lebih komprehensif tentang mutasi EGFR pada kanker paru.
Preoperative Neoadjuvant Hormonal Therapy and Neoadjuvant Chemotherapy for Stage 3B and 4 Breast Cancer Patients in Dharmais Hospital-National Cancer Center, Indonesia: A Cohort Study Karsono, Ramadhan; Purwanto, Denni Joko; Haryono, Samuel J.; Karsono, Bambang; Sari, Lenny; Pratiwi, Yulia; Aryandono, Teguh
Indonesian Journal of Cancer Vol 12, No 4 (2018): October-December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (891.03 KB) | DOI: 10.33371/ijoc.v12i4.604

Abstract

Background: There are no data of efficacy comparison between primary systemic therapy in stage 3B and 4 breast cancer patients in Indonesia. This study compared long term outcomes of breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT)Methods: This was a cohort study conducted from 2011 to 2017. A total of 122 patients with stage 3B and 4 breast cancer received NAHT (n = 62) or NACT (n = 60) within a 6 cycles for NACT and 6 months for NAHT were included. Patients were excluded if they had a mastectomy before treatment, were pregnant, had been given hormonal therapy or chemotherapy before, had a contra-indication of chemotherapy, had a contra-indication of salpingo-oophorectomy bilateral for premenopausal patients, and declined to enter this study. The primary outcome of this study was overall survival. The outcomes were analysed using Kaplan-Meier for survival analysis and cox proportional hazard regression to estimate the hazard ratio.Results: There was a statistically significant difference in overall survival (p = 0.038). Median overall survival for NAHT patients was 1265 days and for NACT patients was 654 days. The hazard ratio showed NACT patients had a higher risk than NAHT patients (1.7 95% CI 1.03 – 2.9). Pathological complete response rate was higher in the NACT group than in the NAHT group (3.3% vs. 0%).Conclusions: Neoadjuvant hormonal therapy was superior to neoadjuvant chemotherapy in term of overall survival.
Co-Authors Bambang Karsono DENNI JOKO PURWANTO, DENNI JOKO Haryono, Samuel J. Karsono, Ramadhan Purwanto Purwanto Teguh Aryandono Yulia Pratiwi